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Abstract
Background. Little information is available about the
long-term outcome of renal transplantation in adults with
Henoch-Schonlein purpura (HSP).
Methods. We compared the outcomes of 17 patients with
HSP who received 19 renal transplants with those of 38
controls matched for time of transplantation, age, gender
and source of donor. The mean post-transplant follow-up
was 109± 99months forHSPpatients and 110± 78months
for controls.
Results. The actuarial 15-year patient survival was 80% in
HSP patients and 82% in controls, and the death-censored
graft survival was 64% in HSP patients and in controls. The
risks of acute rejection, chronic graft dysfunction, arterial
hypertension and infection were not different between the
two groups. In eight grafts (42%) recurrence ofHSP nephri-
tis was found (0.05/patient/year). In spite of therapy, one pa-
tient died and four eventually restarted dialysis respectively
10, 32, 35 and 143 months after renal transplant. Seventy-
one percent of grafts transplanted in patients with necrotiz-
ing/crescentic glomerulonephritis of the native kidney had
HSP recurrence in comparison to 12% of recurrences in
patients with mesangial nephritis (P = 0.05)
Conclusions. Long-term patient and allograft survival of
HSP patients was good. However, 42% of HSP patients,
particularly those with necrotizing/crescentic glomeru-
lonephritis of the native kidneys, developed a recurrence
of HSP nephritis that eventually caused the loss of the graft
function in half of them.
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Introduction
Henoch-Schonlein purpura (HSP) is a small-vessel vas-
culitis that affects the kidney in about 20–28% of children
and 49–83% of adults [1]. In a large Italian multicentre
study, renal survival rates at 10 years were 90% in children
and 76% in adults [1]. However, the data concerning the
outcome of adults with HSP submitted to renal transplant
are very scanty [2,3], probably due to the low frequency
of the disease. Only a few case reports [4–6] have under-
lined the systemic and/or the graft recurrence of the orig-
inal disease with consequent loss of graft function. Three
papers have reported the outcome of a cohort of HSP re-
nal transplant patients [7–9]. Almost all the patients were
children. About half of the patients lost graft function in
the long term, mostly due to chronic rejection. The risk of
recurrence varied between 21% and 88%. The impact of
recurrence was varied, with some patients developing graft
failure while others maintaining stable graft function.
The short- and long-term outcome, the frequency and the
risk factors for clinical recurrences of HPS nephritis after
renal transplantation in adults remain largely unknown.
The aims of this single-centre retrospective analysis were
(1) to compare the long-term patient and renal allograft sur-
vival of HSP patients with those of well-matched controls,
(2) to compare the long-term complications in these two
groups and (3) to assess the rate and the consequences of
recurrence in renal transplant recipients with HSP.
Subjects and methods
Patients
We considered for this study HSP patients who had re-
ceived a kidney transplantation at Ospedale Maggiore of
Milan between March 1979 and January 2006. The diagno-
sis of HSP was based on clinical criteria (purpuric papules
involving the extensor surfaces of the lower extremities and
buttocks symmetrically, arthralgia and periarticular oedema
of the knees, ankles, elbows and wrists, abdominal pain
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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with vomiting and diarrhoea, microscopic or macroscopic
haematuria, proteinuria and deterioration of renal function)
as well as renal biopsy (segmental or diffuse granular depo-
sition of IgA in the mesangium and/or along the glomeru-
lar capillary walls; IgA should be prevalent on the other Ig
classes).
Renal allograft recipients transplanted before and af-
ter patients with HSP, matched for age (±5 years),
gender and source of the donor (deceased or living)
were considered as controls. None of the 38 controls
showed any clinical sign or symptom of HSP. One pa-
tient had polycystic kidney disease, 10 had congenital uri-
nary tract abnormalities, 8 a clinical diagnosis of chronic
glomerulonephritis, 10 biopsy-proven glomerulonephritis
(focal/segmental glomerulosclerosis 4 patients, membra-
nous glomerulonephritis 2 patients, IgM nephropathy 1 pa-
tient, membranoproliferative glomerulonephritis 1 patient),
1 renal AA amyloidosis, 1 Alport’s syndrome, 1 Fabry’s dis-
ease, 3 chronic pyelonephritis and 3 nephroangiosclerosis.
All HSP patients and controls were Caucasian.
Definitions
Acute rejection was diagnosed on the basis of a double-
checked increase of 20% or more in plasma creatinine over
the baseline not explained by other causes. In patients who
underwent graft biopsy the severity of rejection and the
classification of chronic histological lesions were scored
retrospectively according to the recently revised Banff clas-
sification [10]. Unspecific sclerosing lesions were defined
by the presence of interstitial fibrosis with tubular atrophy
and glomerular and arteriolar sclerosis, without evidence of
any specific etiology. Chronic rejection was defined by the
presence of chronic allograft arteriopathy and/or chronic
transplant glomerulopathy.
All renal biopsies were evaluated by light microscopy
and immunofluorescence. Histologic recurrence of HSP
nephritis in the graft was defined by the presence of IgA in
the mesangium and/or along the glomerular capillary walls.
Immunosuppression
Eight grafts (42%) in the HSP group and 22 (58%) in
the control group received a triple therapy (cyclosporine
or tacrolimus plus azathioprine or mycophenolate mofetil,
plus steroids). SixHSP patients (31%) and eight (21%) con-
trols received cyclosporine plus steroids. Two HSP patients
and six controls received steroids plus azathioprine (10%
versus 16%). TwoHSP patients (10%) and one control (3%)
received sirolimus plus cyclosporine and steroids. One pa-
tient in each group was treated with cyclosporine only.
Acute cellular rejections were treated with intravenous
methylprednisolone pulse (MP) therapy, and acute vascular
rejections with anti-thymocyte globulins.
Statistical analysis
The statistical package S-Plus was used to analyse sample
data. Means ± SDs were used for descriptive analysis. The
t-test and the non-parametric Wilcoxon test were used to
investigate differences between the two groups of patients.
Fig. 1. Kaplan–Meier estimates of patient survival in renal-transplanted
patients with Henoch–Schonlein purpura (solid line) and in controls
(dashed line).
Cross-tabulated data were analysed by the chi-square test,
or by the Fisher test when the expected cell count was
<5. Survival curves were drawn using the Kaplan–Meier
estimate and compared using the log-rank test.
Results
Of the 1790 renal transplants performed in our Renal Unit
between March 1979 and January 2006, 19 (1%) were per-
formed on 17 patients (15 adults, 2 adolescents aged 12
and 14 years, respectively) with HSP (2 patients had 2
transplants). Fifteen (88%) had been submitted to renal
biopsy before transplantation; of them, five had necrotiz-
ing/crescentic glomerulonephritis involving 25% to >50%
of glomeruli. In the other two patients the diagnosis of HSP
was based on clinical and biological features. Diagnosis of
HSP and that of nephritis were made in mean 155 ± 89
months and 147 ± 83 months, respectively, before trans-
plantation. HSP patients had been on dialysis for 44 ± 33
months before transplantation. At the time of transplan-
tation all HSP patients showed clinical quiescence of the
disease for at least 12 months.
The demographic characteristics of HSP patients, the
number ofHLAmismatches and the levels of panel-reactive
antibodies (PRA) revealed no differences from those of the
controls. (Table 1).
Patient and graft survival
The mean follow-up after renal transplantation was 109 ±
99 months for patients with HSP and 110 ± 79 months
for controls. The actuarial 10- and 15-year patient survival
rates were 92% and 80% in HSP patients and 96% and
82%, respectively, in controls (P = ns) (Figure 1). Two
HSP patients died, one in a car accident and the other for
desiccation of aortic aneurysm (last serum creatinine 1.3
and 1.6 mg/dl). In the control group, three patients died,
two from cardiac infarct and one because of an accident at
work (last serum creatinine 1.2, 1.7 and 1.8 mg/dl).
In HSP patients, six grafts were lost (31%), due to acute
vascular rejection in one patient, renal recurrence of HSP
in four patients and chronic rejection in the other patient.
Nine graft failures occurred in the control group (23%).
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Table 1. Demographic and laboratory characteristics of Henoch–Schonlein purpura and control recipients at renal transplantation
HSP (19 grafts) Controls (38 grafts) P
Age (years) at transplant (mean ± SD) 29 ± 12 31 ± 14 ns
Sex (male/female) 13/6 26/12 ns
Living/deceased donors 7/12 14/24 ns
Length of dialysis (months) (mean ± SD) 45 ± 34 32 ± 25 ns
CAPD/HD 1/17 8/29 ns
HCV positive/negative 5/14 8/30 ns
Follow-up post transplant (mean ± SD) 109 ± 99 110 ± 79 ns
HLA mismatches (number) 3 ± 1.41 2.75 ± 1.54 ns
Panel reactive antibodies (No. of positive) 2 3 ns
Nadir serum creatinine (mg/dl) (mean ± SD) 1.3 ± 0.4 18 ± 2.1 ns
CAPD = continuous ambulatory peritoneal dialysis; HD = haemodialysis.
Fig. 2. Kaplan–Meier estimates of renal survival probability censored for
death in renal-transplanted patients withHenoch–Schonlein purpura (solid
line) and in controls (dashed line).
Table 2. Main complications after kidney transplantation
HSP patients Control patients P
Delayed graft function ≥3 days 0 2 ns
Acute rejections 10 13 ns
Vascular rejections 1 2
Cellular rejections 2 1
Clinical acute rejections 7 10
Chronic rejection 2 4 ns
Unspecific sclerosing lesions 1 6 ns
Arterial hypertension 16 (84%) 33 (86%) ns
No. of patients with infections 10 (52%) 17 (45%) ns
There was one case of primary non-functioning kidney,
one patient had acute renal artery thrombosis, and the other
seven patients lost the graft in mean 89 ± 54 months after
transplantation: three due to chronic rejection and four due
to aspecific sclerosing lesions. The actuarial 10- and 15-
year graft survival rates censored by death were 75% and
64% in HSP patients and 70% and 64%, respectively, in the
control group (P = ns) (Figure 2).
Posttransplant complications (Table 2)
There were no significant differences betweenHSP patients
and controls in the number of delayed graft functions, acute
and chronic rejections, unspecific chronic lesions or severe
infections.
Considering HSP grafts still functioning at the end of
the follow-up (13 out of 19), the mean levels of serum
creatinine and daily proteinuria were 1.6 ± 0.7 mg/dl and
0.3 ± 0.2 g/24 h, respectively.
Outcome of Henoch-Schonlein purpura during renal
transplantation (Table 3)
In 12 of the 19 grafts, 16 biopsies were performed during
the follow-up for clinical reasons, such as primary non-
function or impairment of graft function and/or proteinuria
and/or haematuria. Seven biopsies performed in four grafts
did not show IgA immune deposits at immunofluorescence.
In the remaining eight grafts (42%) transplanted in seven
patients a renal recurrence of HSP was documented in a
mean 30± 41 months after transplantation; the relapse rate
was 0.05/patient/year. In their native kidneys, four patients
who received six grafts had necrotizing/crescentic glomeru-
lonephritis, one patient had mesangial proliferation, in an-
other patient only immunofluorescence was available and
in the last patient a biopsy of the native kidney was not
performed.
The first renal manifestation of the recurrence was mi-
croscopic haematuria in seven and macroscopic haematuria
in the other graft.
In five patients, proteinuria and a worsening of graft
function developed during the following months (patients
1, 2, 3, 6, 7). In three of them (patients 1, 2, 3) the clin-
ical recurrence of the disease occurred within the first
year after transplant. The biopsy of their native kidneys
showed crescentic glomerulonephriitis in 25–50% of the
glomeruli. After transplantation their immunosuppressive
regimen was steroids, cyclosporine and azathioprine in pa-
tient 1; steroids, cyclosporine and sirolimus in patient 2
and steroids and cyclosporine in patient 3. Graft biop-
sies showed mesangial proliferation with a variable ex-
tent of extracapillary and necrotizing glomerular lesions
in all of them. At immunofluorescence, IgA was present
in the mesangium and along the capillary walls, while fib-
rin was observed in necrotic areas. The recurrence was
treated with a course of 3 MP pulses in patients 1 and 2
and with cyclophosphamide 1 mg/kg/day for 4 months in
patient 3. In spite of the therapy, nephrotic syndrome de-
veloped and graft function progressively declined, and all
three patients restarted haemodialysis 10, 32 and 35months,
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respectively, after transplantation. Patients 2 and 3 re-
ceived a second deceased graft. Patient 3 lost the second
graft due to irreversible vascular rejection 1 month af-
ter transplant. Patient 2 developed microscopic haematuria
8 months after the second transplant. The graft biopsy doc-
umented the presence of mild mesangial proliferation and
IgA immunodeposits. Immunosuppressive therapy (steroid,
cyclosporine, micophenolic acid) was not modified. At last
observation, 6 months later, isolated microscopic haema-
turia persisted with normal graft function.
In patient 6 the recurrence of HSP nephritis developed
10 years after transplant. In this case, the original diag-
nosis of HSP was based on clinical grounds and no renal
biopsy of the native kidney was performed. The immuno-
suppressive therapy consisted of steroids and cyclosporine.
Six years after transplantation a graft biopsy revealed ini-
tial signs of chronic rejection but without deposits of IgA at
immunofluorescence. Mycophenolic acid was added to the
immunosuppressive therapy. Four years later microscopic
haematuria and proteinuria developed followed by a wors-
ening of graft function. A second graft biopsy showed ex-
tracapillary proliferation and necrosis in 20% of glomeruli,
focal and segmental glomerular sclerosis, interstitial fibro-
sis and arteriolar hyalinosis withmesangial and parietal IgA
immunodeposits. In spite of a course of 3 MP pulses fol-
lowed by cyclophosphamide 2 mg/kg/day for 2 months in
substitution of cyclosporine and mycophenolic acid, graft
function progressively worsened and the patient eventually
restarted dialysis 14 months later.
Seventeen months after renal transplant, patient 7 devel-
oped fever, arthralgias, purpuric lesions on the legs and ab-
domen with macroscopic haematuria, nephrotic syndrome
and renal failure. At graft biopsy, necrotizing/crescentic
glomerulonephritis in 40% of glomeruli and IgA immun-
odeposits were present. Treatment with 5 MP pulses within
2 weeks, while continuing cyclosporine, rapidly reversed
the extrarenal manifestations. Renal function returned to
the basal value within 2 months; proteinuria slowly disap-
peared and microscopic haematuria persisted. Seven years
later a new renal and extrarenal HSP flare occurred that
completely reversed after a new course of 3 MP pulses.
At repeated graft biopsy, 30% of glomeruli were sclerotic,
while fresh crescents with necrosis were present in many
other glomeruli. The patient eventually died 12 years after
transplantation due to desiccation of aortic aneurysm with
serum creatinine of 1.8 mg/dl and proteinuria of 0.9 g/day.
The last two patients (patients 4 and 5) in whom the graft
HSP recurrence was documented 3 years after transplant,
when microscopic (patient 4) and macroscopic (patient 5)
haematuria developed, did not receive additional therapies.
The biopsies of their native kidneys showed crescentic
glomerulonephritis in patient 4 and mesangial proliferation
in patient 5. Graft biopsies in both patients showed a mild
increase in mesangial cells in a minority of the glomeruli,
and IgA immunodeposits inmesangium. Haematuria disap-
peared a few months later in both patients. Thirteen years
after transplantation, slow but progressive impairment of
graft function occurred in patient 4. Considering that the pa-
tient was not compliant to therapy, the deterioration of graft
function may be attributed to chronic rejection, although a
role of the HSP recurrence cannot be excluded. Patient 5
continued to have satisfactory graft function 10 years after
transplantation.
There were no significant differences between the 8
grafts in whom the recurrence occurred and the other 11
for any clinical or biochemical or therapeutical features
(Table 4); in particular the time from diagnosis to dialysis in
the native kidney was not different between the two groups.
Five out of seven grafts (71%) of patients in whom the
biopsy of the native kidneys showed necrotizing/crescentic
glomerulonephritis had graft HSP recurrence, while only
one out of nine patients (12%) with pure mesangial nephri-
tis of the native kidney developed a graft recurrence (P =
0.05) (Table 4).
At last observation, five out of the eight recurrent grafts
lost their function, due to recurrence of HPS nephritis in
four and due to sudden vascular rejection in one; one other
patient had severe impairment of graft function and the last
patient died.
Discussion
In this study, we have reported our single-centre experience
with 17 HSP adults who received 19 renal transplants fol-
lowed for amean of 9 years, a fairly long follow-up never re-
ported until now. The majority were adults and were treated
with calcineurin inhibitors after transplantation. We used
as controls those patients who were transplanted before and
after those with HSP and matched for the variables that
could influence the outcome of renal transplant. No data
are available about the survival of HPS children or adults
submitted to renal transplant. In this series, the actuarial
15-year patient survival rate in HSP patients was 80% and
82% in the control group.
Hasengawa [7] reported a graft survival rate of 50% at
10 years in 15 HSP children submitted to 17 renal trans-
plantations, but no comparison with a control group was
made. In our series, the actuarial 15-year graft survival rate
censored by death was 64% in HSP patients and in controls.
Our data underline that patients affected by HSP can obtain
a good graft survival even in the long term. In patients with
HSP the number of acute and chronic rejections and the
risk of developing infections were comparable to those of
controls. No data are available about these complications in
the published studies.
The risk of HSP recurrence after renal transplantation is
still unclear in adults and few data are available in children.
In 15 children who received 17 renal transplants, sub-
mitted to serial allograft biopsies, Hasegawa [7] found his-
tological recurrence of HSP in nine grafts (53%). In five
patients only, did proteinuria and haematuria develop during
the follow-up and two lost the graft due to recurrence.Meul-
ders [9] described the outcome of 14 renal transplants in 10
HSP patients (7 children and 3 adults) followed for a mean
period of 66 months. Histological recurrence was docu-
mented in three patients (21%) associatedwith development
of proteinuria, haematuria and irreversible deterioration of
renal function in two (14%). In addition, five other patients
lost the kidney due to chronic rejection. Habib [8] docu-
mented a histological recurrence of HSP in eight of nine
HSP-transplanted children; proteinuria, haematuria and
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Table 4. Demographic, clinical and laboratory characteristics of patients with Henoch-Schonlein purpura who relapsed and those who did not
Grafts with recurrent
renal HSP: 8
Non-recurrent
grafts: 11
P
Age at tx (years) (mean ± SD) 31.2 ± 10.4 30.1 ± 14.6 ns
Sex (male/female) 6/2 6/5 ns
Months between diagnosis of HSP and ESRD 145.1 ± 102 140 ± 92 ns
(months) (mean ± SD)
Duration of dialysis (months) (mean ± SD) 37 ± 19 50 ± 40 ns
Type of dialysis (HD/CAPD) 7/1 11/0 ns
Crescentic GN of the native kidney 71% 12% 0.05
Follow-up post-tx (months) (mean ± SD) 90 ± 77 123 ± 114 ns
Deceased/living donors 5/3 7/4 ns
HCV positivity (yes/no) 1/7 4/7 ns
Calcineurin inhibitors therapy
No. of grafts 8 9 ns
Basal serum creat. (mg/dl) (mean ± SD) 1.6 ± 0.3 1.2 ± 0.25 0.013
Arterial hypertension 7/0 9/3 ns
Acute rejection 3 7 ns
Chronic rejection 1 1 ns
Unspecific sclerosing lesions 1 0 ns
No. of patients with infections 3 7 ns
Final serum creat. (mg/dl) (mean ± SD) 1.8 ± 0.9 14 ± 0.5 ns
Final proteinuria (g/24 h) (mean ± SD) 0.4 ± 0.2 0.3 ± 0.3 ns
No. of deaths 1 1 ns
No. of lost kidneys 4 2 ns
HSP = Henoch-Schonlein purpura, tx = transplant, ESRD = end-stage renal disease, CAPD = continuous ambulatory peritoneal dialysis, HD =
haemodialysis, GN = glomerulonephritis, creat. = creatinine.
progressive deterioration of graft function developed dur-
ing the follow-up in only one patient. In contrast, Cameron
[11] found no histological recurrence in 7 out of the 10
HSP-transplanted children.
In adults with IgA nephropathy too, allograft recurrences
of mesangial IgA deposits have been occasionally noted
even though there have been no clinical manifestations
of glomerulonephritis or with only minimal haematuria
[12,13]. Since IgA nephropathy and HSP probably share
[14] similar immune pathogenetic mechanisms it is not sur-
prising to observe also in HSP patients histological recur-
rences in allografts without clinical signs. The prognostic
significance of these forms of histological recurrences, not
complicated by the development of clinical manifestations,
is not clarified. However, they do not seem to unfavourably
impact on the graft survival.
In our study we performed graft biopsies only for clin-
ical purposes. However, in four grafts, on which seven re-
nal biopsies were performed, no IgA immunodeposits were
found, while in another eight grafts histological recurrences
of HSP were documented. Three patients recurred with mi-
croscopic or macroscopic haematuria, and all had mild his-
tological lesions. These clinical manifestations were tran-
sient in twowhile haematuria persisted in the last patient. At
the last observation, 14 months and 7 years after transplant,
respectively, two patients had good renal function, while
the third patient, 18 years after transplant, had impaired
graft function, although without urinary abnormalities. In
this last case, even in the absence of histological documen-
tation, the renal dysfunction was unlikely to have been due
to the progression of nephritis. In the other five patients,
the clinical manifestations as well as the histological le-
sions were more severe. In spite of the reinforcement of
immunosuppression, all but one lost the graft. Altogether
we found a histological recurrence of 42% in HSP patients,
but the rate of recurrence rose to 64% if only those patients
who received a post-transplant biopsy were evaluated. A
comparable rate of recurrence was observed in our series
of 106 transplanted patients with IgA nephritis followed
for a mean period of 70 months: 35% of all patients and
65%, if only patients submitted to graft biopsy were con-
sidered. [15]. In contrast, the median time for histological
recurrence was longer in our IgA patients (52 months) than
in HSP patients (30 months), and the percentage of graft
failure due to recurrence was lower in IgA (11%) than in
HSP (50%) patients. These data underline that, as for the
course of these diseases in the native kidney, the recurrence
of HSP pertains a worse graft prognosis than that of IgA
nephritis.
As recently shown in the native kidney of patients with
HSP [1] the worsening of graft function was heralded in our
five patients by the progressive increase of proteinuria. In
contrast to what has been reported by others [9,16] we did
not observe either a shorter duration of the original disease
or a higher incidence of grafts from living donors in patients
who relapsed than in those who did not. Instead, a signif-
icantly higher rate of recurrences of HSP nephritis was
observed in our patients with crescentic glomerulonephri-
tis of the native kidney. Although this observation is based
on a small series, it is possible to speculate that in these
patients crescentic nephritis represents a more aggressive
form of the original disease that recurs in the graft in spite
of immunosuppression.
Few data are available concerning the treatment of the re-
currence of HSP in the graft [7,9,17,18], and in the majority
of those cases the therapywas unsuccessful [7,9]. The use of
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the new immunosuppressive agents and the reinforcement
of therapy with i.v. MP pulse and/or oral cyclophosphamide
did not prevent the recurrence and/or the progression of
graft dysfunction in the majority of our recurrent patients.
In conclusion, our study, although retrospective and
based on a small sample size, suggests that transplanted
patients with HSP may have good patient and graft sur-
vival, not only in the short term but also up to 15 years.
Therefore, patients with HSP may be considered as suit-
able candidates for kidney transplantation. However, the
risk of recurrence is high, and in spite of an aggressive
therapy, the recurrence can cause graft loss in the majority
of patients. Patients with crescentic glomerulonephritis of
the native kidneys, who seem to be at higher risk of recur-
rence, should be closely monitored, particularly during the
first years after transplant.
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